

Id	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	Reasons for Delay	Comments	Reasons for delay correspond to:
168681	19/SC/0344	263202	Global SYMPLI CITY Registry	No		36			23/05/2019	04/12/2019	26/11/2019	01/10/2019	09/01/2020	Please Select...	A - Permissions delayed /denied D - Sponsor Delays	Delay in set up due to HRA approvals.SIV postponed from Nov 2019 due to HRA delay in approval. Re-booked for Jan'20 due to sponsor availability. 17/01/2020 still awaiting sponsor green light to open to recruitment.Site selection letter from sponsor was received in May 2019, however	Sponsor	

																	the full document pack was not received by R&D Office, therefore site selection date has been entered at 04/12/19. Sponsor had signed CTA in October 2019, with NHS site signing once regulatory approvals received.	
168682	19/EM/0016	253279	Evaluation of Efficacy and Safety of Sarilumab in Patients With GCA	No		17			10/09/2018	01/11/2019	25/10/2018	12/11/2019	18/11/2019	Please Select...	19/12/2019	B - Suspended by sponsor	suspended recruitment due to COVID pandemic	Sponsor
168683	19/NW/0363	250571	"I4V-MC-JAJA Baricitinib in RA (RA-BRIDGE)"	Yes	18/08/2020	31	249	280	29/03/2019	12/11/2019	08/08/2019	18/11/2019	13/12/2019	Please Select...	13/12/2019	E - Staff availability issues	Staff availability issues to commence trial	NHS Provider
168684	18/SS/0085	243640	Alpha-2 agonist	Yes	05/12/2019	29	27	56	24/10/2018	10/10/2019	14/12/2018	25/11/2019	08/11/2019	Please Select...	25/11/2019	B - Suspended	study suspended	Sponsor

			s for sedation (A2B Trial)												ded by sponsor	ded due to COVID. Re-opened to recruitment on 20/07/2020	
168685	18/ES/0119	245233	Stopping Aminosalicylate Therapy in Inactive Crohn's Disease (STATI C)	No					16/11/2018	16/12/2019	09/11/2018			Please Select...	B - Suspended by sponsor	set-up suspended due to COVID.	Sponsor
168686	19/SC/0021	249552	(OPTIM AS Trial) OPTimal TIMing of Anticoagulation after acute ischaemic Stroke: a randomised controlled trial	Yes	04/02/2020	56	20	76	19/12/2018	20/11/2019	04/04/2019	15/01/2020	15/01/2020	Please Select...	E - Staff availability issues	PI could not attend planned SIV, date rescheduled to accommodate	NHS Provider
168687	18/YH/0483	237481	BIOSTREAM HF: Observation of clinical routine care for heart failure patients implanted with BIOTRONIK CRT devices	Yes	05/03/2020	15	7	22	19/09/2019	12/02/2020	14/10/2019	17/02/2020	27/02/2020	Please Select...	D - Sponsor Delays	delay with receiving sponsor greenlight to start recruitment.	Sponsor

168688	19/YH/0158	262107	TRANSITION - An open-label, randomized, Phase IV study, to assess the efficacy and safety of tildrakizumab in patients with moderate-to-severe chronic plaque psoriasis who are non-responders to dimethyl fumarate therapy	No		42				14/01/2019	16/01/2020	26/07/2019	18/02/2020	27/02/2020	Please Select...	03/03/2020	H - Contracting delays	Following SIV, CTA had to be amended to reduce recruitment target.	Both
168689	19/LO/1035	264950	G PLUS - A Phase 3b, Multicenter, Interventional, Randomized, Placebo-controlled Study Investigating the Efficacy	No		4				11/01/2019	06/01/2020	29/07/2019	12/12/2019	10/01/2020	Please Select...	20/01/2020	D - Sponsor Delays E - Staff availability issues	December 2019 both CT pharmacists off sick. CRA off sick until 09/01/2020. 17/01/2020 Drs not completed IWRS training	Both

			and Safety of Guselkumab for the Treatment of Palmoplantar non-Pustular Psoriasis														so sponsor could not issue green light to commence recruitment. 10/02/2020 green light received.	
168690	19/NE/0328	270912	M19-164: A Phase 3b, multicenter, interventional, open-label study of adult subjects with moderate to severe plaque psoriasis who have a suboptimal response to secukinumab or ixekizumab and are switched to risankizumab.	No		0			24/06/2019	05/02/2020	19/11/2019	20/12/2019	05/02/2020	Please Select...	10/02/2020	D - Sponsor Delays E - Staff availability issues	SIV had to be rescheduled from Nov to Jan as approvals not received. Sponsor would not issue green light until Sub-PI in post. 10/02/2020 green light received.	Both
169970	20/YH/004	272789	Long-Term Safety and Efficacy	Yes	20/08/2020	15	21	36	02/10/2019	15/07/2020	09/06/2020	23/07/2020	30/07/2020	Please Select...	06/08/2020	D - Sponsor Delays	confirmation of C&C issued 30/07/2	Sponsor

			of BMS-986165 in Subjects with Psoriasis														020, sponsor replied that they should have us greenlighted by the end of next week due to internal processes. 06/08/2020 approval received to recruit.	
169971	19/WA/0365	261306	CAIN457M2301E1 (SUN Extension) Secukinumab in hidradenitis suppurativa	Yes	03/09/2020	3	14	17	16/10/2019	17/08/2020	23/01/2020	19/08/2020	20/08/2020	Please Select...	01/09/2020	D - Sponsor Delays	Had to wait for sponsor greenlight, they would not issue until IMP received at site.	Sponsor
169972	20/SS/004	262376	LPS15497	No		4			18/03/2019	07/09/2020	09/07/2020	07/09/2020	11/09/2020	Please Select...	22/10/2020	J - Other	SIV planned for April 2020 but had to be postponed due to COVID 19 pandemic.	Neither
169973	19/YH/0400	271539	A Multicenter, Double-blind, Placebo-	No					17/07/2019	19/09/2020	09/01/2020			Please Select...		D - Sponsor Delays E - Staff availability issues	SIV not available until after 15/04/2020 as spec by	Both

			<p>controlled, Randomized Withdrawal, Parallel Group Study of Patiromer for the Management of Hyperkalemia in Subjects Receiving Renin-Angiotensin-Aldosterone System Inhibitor (RAASi) Medications for the Treatment of Heart Failure (DIAMOND)</p>														<p>J - Other</p>	<p>sponsor . SIV delayed due to COVID 11/08/2020 SIV postponed due to PI unavailability due to personnel reasons . to be re-booked. SIV held 10/09/2020 - pharmacy queries to resolve. 24/09/2020 so can now issue C&C 28/10/2020 STILL WAITING FOR GREEN LIGHT FROM SPONSOR.</p>	
--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	------------------	---	--